ATLAS PHARMA CONSULTING LIMITED

ATLAS PHARMA CONSULTING LIMITED

ATLAS PHARMA CONSULTING LIMITED - Company Information

Print Friendly Version

ATLAS PHARMA CONSULTING LIMITED

Company Registration Number:
12799003 (England and Wales)

Unaudited abridged accounts for the year ended 31 December 2021

Period of accounts

Start date: 07 August 2020

End date: 31 December 2021

ATLAS PHARMA CONSULTING LIMITED

Contents of the Financial Statements

for the Period Ended 31 December 2021

Balance sheet
Notes

ATLAS PHARMA CONSULTING LIMITED

Balance sheet

As at 31 December 2021


Notes
17 months to 31 December 2021


£
Called up share capital not paid: 0
Fixed assets
Intangible assets:   0
Tangible assets: 3 844
Investments:   0
Total fixed assets: 844
Current assets
Stocks: 0
Debtors:   31,000
Cash at bank and in hand: 30,424
Investments:   0
Total current assets: 61,424
Creditors: amounts falling due within one year:   (356,652)
Net current assets (liabilities): (295,228)
Total assets less current liabilities: (294,384)
Creditors: amounts falling due after more than one year:   0
Provision for liabilities: 0
Total net assets (liabilities): (294,384)
Capital and reserves
Called up share capital: 1,000
Share premium account: 0
Revaluation reserve: 0
Other reserves: 0
Profit and loss account: (295,384)
Shareholders funds: (294,384)

The notes form part of these financial statements

ATLAS PHARMA CONSULTING LIMITED

Balance sheet statements

For the year ending 31 December 2021 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 07 July 2022
and signed on behalf of the board by:

Name: Claire Eldridge
Status: Director

The notes form part of these financial statements

ATLAS PHARMA CONSULTING LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2021

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

Turnover policy

Turnover represents amounts received or receivable in respect of goods and services supplied during the year, net of VAT and trade discounts

Tangible fixed assets and depreciation policy

Tangible fixed assets are stated at cost less depreciation. Depreciation is provided at rates calculated to write off the cost less estimated residual value of each asset over its expected useful life, as follows:Fixtures, fittings & equipment - 3 years straight line

ATLAS PHARMA CONSULTING LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2021

2. Employees

17 months to 31 December 2021
Average number of employees during the period 1

ATLAS PHARMA CONSULTING LIMITED

Notes to the Financial Statements

for the Period Ended 31 December 2021

3. Tangible Assets

Total
Cost £
Additions 1,215
Disposals 0
Revaluations 0
Transfers 0
At 31 December 2021 1,215
Depreciation
Charge for year 371
On disposals 0
Other adjustments 0
At 31 December 2021 371
Net book value
At 31 December 2021 844